MX2023008042A - Formas cristalinas de un modulador del receptor de rianodina y usos del mismo. - Google Patents
Formas cristalinas de un modulador del receptor de rianodina y usos del mismo.Info
- Publication number
- MX2023008042A MX2023008042A MX2023008042A MX2023008042A MX2023008042A MX 2023008042 A MX2023008042 A MX 2023008042A MX 2023008042 A MX2023008042 A MX 2023008042A MX 2023008042 A MX2023008042 A MX 2023008042A MX 2023008042 A MX2023008042 A MX 2023008042A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- ryanodine receptor
- receptor modulator
- diseases
- benzothiazepin
- Prior art date
Links
- 102000042094 ryanodine receptor (TC 1.A.3.1) family Human genes 0.000 title abstract 3
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 title abstract 3
- 229940075993 receptor modulator Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- JIGDAUOKKYKRKO-UHFFFAOYSA-N 4-[(7-methoxy-3,5-dihydro-2h-1,4-benzothiazepin-4-yl)methyl]benzoic acid Chemical compound C1C2=CC(OC)=CC=C2SCCN1CC1=CC=C(C(O)=O)C=C1 JIGDAUOKKYKRKO-UHFFFAOYSA-N 0.000 abstract 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 208000023178 Musculoskeletal disease Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente divulgación se refiere a las formas cristalinas del compuesto hemifumarato del ácido 4-[(7-metoxi-2,3-dihidro-1,4 benzotiazepina-4(5H)il)metil]benzoico, composiciones farmacéuticas que comprenden estos compuestos y usos de estos para tratar enfermedades y padecimientos asociadas con la disfunción del receptor de rianodina (RyR), en particular, trastornos y enfermedades cardiacas y musculoesqueléticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135083P | 2021-01-08 | 2021-01-08 | |
| PCT/US2022/011640 WO2022150603A1 (en) | 2021-01-08 | 2022-01-07 | Crystalline forms of a ryanodine receptor modulator and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008042A true MX2023008042A (es) | 2023-09-11 |
Family
ID=82358322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008042A MX2023008042A (es) | 2021-01-08 | 2022-01-07 | Formas cristalinas de un modulador del receptor de rianodina y usos del mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11504383B2 (es) |
| EP (1) | EP4274580A4 (es) |
| JP (1) | JP2024503045A (es) |
| KR (1) | KR20230129267A (es) |
| CN (1) | CN116887839A (es) |
| AU (1) | AU2022205964A1 (es) |
| CA (1) | CA3177490A1 (es) |
| IL (1) | IL304215A (es) |
| MX (1) | MX2023008042A (es) |
| WO (1) | WO2022150603A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023008042A (es) * | 2021-01-08 | 2023-09-11 | Armgo Pharma Inc | Formas cristalinas de un modulador del receptor de rianodina y usos del mismo. |
| WO2024086819A2 (en) * | 2022-10-21 | 2024-04-25 | Armgo Pharma, Inc. | Diagnosis and treatment of heart failure |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775536A (en) | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
| NZ257843A (en) | 1992-11-09 | 1996-10-28 | Boots Co Plc | 2,3,4,5-tetrahydro-1,4-benzothiazepine derivatives optionally substituted in position-6 by methyl, fluoro or chloro |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| CA2479668A1 (en) * | 2002-03-20 | 2003-10-02 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of quetiapine hemifumarate |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2008060332A2 (en) | 2006-06-02 | 2008-05-22 | The Trustees Of Columbia University In The City Of New York | Methods for treating or reducing muscle fatigue |
| WO2008021432A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of conditions affecting the nervous system |
| WO2008021439A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of cardiac hypertrophy |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| DK2250159T3 (da) | 2008-03-03 | 2012-03-19 | Servier Lab | Fremgangsmåde til fremstilling af benzothiazepiner fra gamma-amino-alkylbenzener |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| EP2708535A1 (en) | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| AU2015374155A1 (en) | 2014-12-30 | 2017-07-20 | Myotherix, Inc. | Novel calcium modulators |
| MX2023008042A (es) * | 2021-01-08 | 2023-09-11 | Armgo Pharma Inc | Formas cristalinas de un modulador del receptor de rianodina y usos del mismo. |
| WO2022246114A2 (en) * | 2021-05-20 | 2022-11-24 | Armgo Pharma, Inc. | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
-
2022
- 2022-01-07 MX MX2023008042A patent/MX2023008042A/es unknown
- 2022-01-07 CA CA3177490A patent/CA3177490A1/en active Pending
- 2022-01-07 AU AU2022205964A patent/AU2022205964A1/en active Pending
- 2022-01-07 CN CN202280016802.4A patent/CN116887839A/zh active Pending
- 2022-01-07 US US17/571,038 patent/US11504383B2/en active Active
- 2022-01-07 EP EP22737182.0A patent/EP4274580A4/en active Pending
- 2022-01-07 WO PCT/US2022/011640 patent/WO2022150603A1/en active Application Filing
- 2022-01-07 KR KR1020237026559A patent/KR20230129267A/ko active Search and Examination
- 2022-01-07 JP JP2023541839A patent/JP2024503045A/ja active Pending
- 2022-10-17 US US17/967,308 patent/US12076327B2/en active Active
- 2022-10-17 US US17/967,301 patent/US12076326B2/en active Active
-
2023
- 2023-07-03 IL IL304215A patent/IL304215A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3177490A1 (en) | 2022-07-14 |
| JP2024503045A (ja) | 2024-01-24 |
| US12076326B2 (en) | 2024-09-03 |
| US20230075141A1 (en) | 2023-03-09 |
| WO2022150603A1 (en) | 2022-07-14 |
| EP4274580A1 (en) | 2023-11-15 |
| US20230069022A1 (en) | 2023-03-02 |
| AU2022205964A1 (en) | 2023-08-17 |
| EP4274580A4 (en) | 2024-12-25 |
| KR20230129267A (ko) | 2023-09-07 |
| CN116887839A (zh) | 2023-10-13 |
| US11504383B2 (en) | 2022-11-22 |
| US12076327B2 (en) | 2024-09-03 |
| US20220226344A1 (en) | 2022-07-21 |
| IL304215A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008042A (es) | Formas cristalinas de un modulador del receptor de rianodina y usos del mismo. | |
| CU24327B1 (es) | Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden | |
| JP6054868B2 (ja) | Ｌｓｄ１のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用 | |
| NO20071660L (no) | Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer | |
| BG63662B1 (bg) | Нови субституирани циклични аминокиселини като фармацевтични средства | |
| NZ588311A (en) | Stabilized atypical antipsychotic formulation to treat psychiatric conditions | |
| JP2015517495A (ja) | ＲＯＲγ活性を阻害し疾患を治療するための二環式スルホン化合物 | |
| HU228436B1 (en) | 6-fluorobicyclo[3.1.0]hexane derivatives | |
| KR20070057970A (ko) | 피페리디닐아미노-티에노[2,3-ｄ]피리미딘 화합물 | |
| MX2023001812A (es) | Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa. | |
| AU2018216954B2 (en) | Piperazine derivatives for influenza virus inhibition | |
| JP2012502104A (ja) | 疾患の治療のためのヒスタミン受容体に対するアミノピリミジン阻害剤 | |
| PA8531001A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| EA200901160A1 (ru) | Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она | |
| GEP20135806B (en) | Lactams as beta secretase inhibitors | |
| BR112022010599A2 (pt) | Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina | |
| ZA200703596B (en) | Thienopyridinone compounds and methods of treatment | |
| WO2008023258A8 (en) | Piperidine derivatives | |
| UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
| MX2024009926A (es) | Composiciones y metodos para tratar trastornos del snc. | |
| NZ613580A (en) | N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes | |
| DE10351903A1 (de) | Neue Kombination | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
| EP1432715B1 (de) | Pyrimidinderivate |